Market Spotlight: Acne
Market Spotlight: Acne
$1,318.00
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.
- Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for acne are in Phase II. Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
- The overall likelihood of approval of a Phase I dermatology-general asset is 23.3%, and the average probability a drug advances from Phase III is 71.1%. Drugs, on average, take 8.7 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III–IV, and 48% in Phase I–II.
- The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
- GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Topical therapy
9 Systemic therapy
10 Physical treatments
11 EPIDEMIOLOGY
14 MARKETED DRUGS
19 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 VB 1953 for Acne (June 16, 2020)
27 DMT310 for Acne (June 10, 2020)
29 FCD105 for Acne (June 2, 2020)
31 Twyneo for Acne (December 30, 2019)
32 ANT-1207 for Acne (June 25, 2019)
33 VB 1953 for Acne (May 13, 2019)
35 VB 1953 for Acne (May 13, 2019)
37 KEY REGULATORY EVENTS
37 Cassiopea’s Winlevi Brings New Drug Class To Acne Market
38 PROBABILITY OF SUCCESS
39 LICENSING AND ASSET ACQUISITION DEALS
39 L’Oreal’s Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
39 Paratek, Almirall Partner To Bring Acne Medicine To China
39 Menlo And Foamix Merge Into Dermatology Play
39 Deals Shaping The Medical Industry, November 2019
39 Deals Shaping The Medical Industry, November 2019
41 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
46 Recent events
47 BIBLIOGRAPHY
47 Prescription information
49 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of acne, 2019–28
19 Figure 2: Overview of pipeline drugs for acne in the US
20 Figure 3: Pipeline drugs for acne, by company
20 Figure 4: Pipeline drugs for acne, by drug type
21 Figure 5: Pipeline drugs for acne, by classification
27 Figure 6: VB 1953 for Acne (June 16, 2020): Phase II – Facial Acne Vulgaris
29 Figure 7: DMT310 for Acne (June 10, 2020): Phase IIb – 003
31 Figure 8: FCD105 for Acne (June 2, 2020): Phase II – Acne Vulgaris
32 Figure 9: Twyneo for Acne (December 30, 2019): Phase III – SGT-65-04, Phase III – SGT-65-05
35 Figure 10: VB 1953 for Acne (May 13, 2019): Phase II – Proof-of-Concept (ex. US)
36 Figure 11: VB 1953 for Acne (May 13, 2019): Phase I – First-In-Human
38 Figure 12: Probability of success in the dermatology-general pipeline
43 Figure 13: Clinical trials in acne
43 Figure 14: Top 10 drugs for clinical trials in acne
44 Figure 15: Top 10 companies for clinical trials in acne
44 Figure 16: Trial locations in acne
45 Figure 17: Acne trials status
46 Figure 18: Acne trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of acne, 2019–28
15 Table 2: Marketed drugs for acne
22 Table 3: Pipeline drugs for acne in the US
26 Table 4: VB 1953 for Acne (June 16, 2020)
28 Table 5: DMT310 for Acne (June 10, 2020)
30 Table 6: FCD105 for Acne (June 2, 2020)
31 Table 7: Twyneo for Acne (December 30, 2019)
33 Table 8: ANT-1207 for Acne (June 25, 2019)
34 Table 9: VB 1953 for Acne (May 13, 2019)
35 Table 10: VB 1953 for Acne (May 13, 2019)
41 Table 11: Historical global sales, by drug ($m), 2015–19
42 Table 12: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Irritable Bowel Syndrome (IBS) 
Sign up to the